Furthermore, the combination of αCD40 plus chemotherapy increased sensitivity to PD-1 / CTLA4 blockade, driving T cell-dependent anti-tumour immunity in a subcutaneous transplantable KPC model, and improving overall survival in the spontaneous KPC model [27]. This evidence concerns the gene CTLA4 and neoplasm.